Use: Labeled indications
- Prednisone delayed-release tablets are a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system…
- for the treatment of certain endocrine conditions
- for palliation of certain neoplastic conditions
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Prednisone delayed-release tablets are indicated in the treatment of the following diseases or conditions: Prednisone delayed-release tablets are a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation (1) for the treatment of certain endocrine conditions (1) for palliation of certain neoplastic conditions (1) 1.1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adults and pediatric populations with: Atopic dermatitis Drug hypersensitivity reactions Seasonal or perennial allergic rhinitis Serum sickness 1.2 Dermatologic Diseases Bullous dermatitis herpetiformis Contact dermatitis Exfoliative erythroderma Mycosis fungoides Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) 1.3 Endocrine Conditions Congenital adrenal hyperplasia Hypercalcemia of malignancy Nonsuppurative thyroiditis Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable 1.4 Gastrointestinal Diseases During acute episodes in: Crohn's Disease Ulcerative colitis 1.5 Hematologic Diseases Acquired (autoimmune) hemolytic anemia Diamond-Blackfan anemia Idiopathic thrombocytopenic purpura in adults Pure red cell aplasia Secondary thrombocytopenia in adults 1.6 Neoplastic Conditions For the treatment of: Acute leukemia Aggressive lymphomas 1.7 Nervous System Conditions Acute exacerbations of multiple sclerosis Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions Sympathetic ophthalmia Uveitis and ocular inflammatory conditions unresponsive to topical steroids 1.9 Conditions Related to Organ Transplantation Acute or chronic solid organ rejection 1.10 Pulmonary Diseases Acute exacerbations of chronic obstructive pulmonary disease (COPD) Allergic bronchopulmonary aspergillosis Aspiration pneumonitis Asthma Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Hypersensitivity pneumonitis Idiopathic bronchiolitis obliterans with organizing pneumonia Idiopathic eosinophilic pneumonias Idiopathic pulmonary fibrosis Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV(+) individual who is also under treatment with appropriate anti-PCP antibiotics. Symptomatic sarcoidosis 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 1.12 Rheumatologic Conditions As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Acute gouty arthritis During an exacerbation or as maintenance therapy in selected cases of: Ankylosing spondylitis Dermatomyositis/polymyositis Polymyalgia rheumatica Psoriatic arthritis Relapsing polychondritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Sjogren's syndrome Systemic lupus erythematosus Vasculitis 1.13 Specific Infectious Diseases Trichinosis with neurologic or myocardial involvement.
Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy.
Contraindications
4 CONTRAINDICATIONS Prednisone delayed-release tablets are contraindicated in patients who have known hypersensitivity to prednisone or to any of the excipients. Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy [see Adverse Reactions (6)]. Known hypersensitivity to prednisone or any excipients in the formulation (4, 6)
US FDA labelDosing: Adult
- Individualize dosing based on disease severity and patient response. The timing of administration should take into account the delayed-release pharmacokinetics and the disease or condition being treated (2, 12.1): Initial dose: Prednisone delayed-release tablets 5 mg administered once per day. Patients currently on immediate-release prednisone, prednisolone, or methylprednisolone should be switched to prednisone delayed-release tablets at an equivalent dose based on relative potency. (2.1, 2.4)
- Maintenance dose: Use lowest dosage that will maintain an adequate clinical response. (2.1)
- Discontinuation: Withdraw gradually if discontinuing long-term or high-dose therapy. (2.1)
- Prednisone delayed-release tablets should be taken daily with food. (2.3, 12.3)
- Prednisone delayed-release tablets should be swallowed whole and not broken, divided, or chewed. (2.3)
2.1 Recommended Dosing
2.1 Recommended Dosing Dosage of prednisone delayed-release tablets should be individualized according to the severity of the disease and the response of the patient. For pediatric patients, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight.
The maximal activity of the adrenal cortex is between 2 am and 8 am and is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocorticoid activity the least when given at the time of maximal activity. Prednisone delayed-release tablet is a delayed-release formulation of prednisone which releases the active substance beginning approximately 4 hours after intake [see Clinical Pharmacology (12.3)].
The timing of prednisone delayed-release tablets administration should take into account the delayed-release pharmacokinetics and the disease or condition being treated. The initial dosage of prednisone delayed-release tablets may vary from 5 to 60 mg per day depending on the specific disease entity being treated. Patients currently on immediate release prednisone, prednisolone, or methylprednisolone should be switched to prednisone delayed-release tablets at an equivalent dose based on relative potency (2.4).
In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period there is a lack of satisfactory clinical response, prednisone delayed-release tablets should be discontinued and the patient transferred to other appropriate therapy.
It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.
It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment.
In this latter situation it may be necessary to increase the dosage of prednisone delayed-release tablets for a period of time consistent with the patient's condition. If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.
2.2 Recommended Monitoring
2.2 Recommended Monitoring Blood pressure, body weight, routine laboratory studies (including 2-hour postprandial blood glucose and serum potassium), and chest X-ray should be obtained at regular intervals during prolonged therapy with prednisone delayed-release tablets. Upper GI X-rays are desirable in patients with known or suspected peptic ulcer disease.
2.3 Method of Administration
2.3 Method of Administration Prednisone delayed-release tablets are for oral administration. Prednisone delayed-release tablets should be taken daily with food. [see Clinical Pharmacology (12.3)] Prednisone delayed-release tablets should not be broken, divided, or chewed because the delayed release of prednisone is dependent on an intact coating [see Description (11)].
2.4 Corticosteroid Comparison Chart
2.4 Corticosteroid Comparison Chart For the purpose of comparison, one 5 mg prednisone delayed-release tablet is the equivalent milligram dosage of the following various corticosteroids: Betamethasone, 0.75 mg Paramethasone, 2 mg Cortisone, 25 mg Prednisolone, 5 mg Dexamethasone, 0.75 mg Prednisone, 5 mg Hydrocortisone, 20 mg Triamcinolone, 4 mg Methylprednisolone, 4 mg These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.
Dosing: Altered kidney function
The maximal activity of the adrenal cortex is between 2 am and 8 am and is minimal between 4 pm and midnight.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The efficacy and safety of prednisone in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (> 2 years of age), and aggressive lymphomas and leukemias (> 1 month of age).
However, some of these conclusions and other indications for pediatric use of corticosteroid, e.g., severe asthma and wheezing, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. The adverse effects of prednisone in pediatric patients are similar to those in adults [see Adverse Reactions (6)].
Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Children who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity.
This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in children than some commonly used tests of HPA axis function.
The linear growth of children treated with corticosteroids by any route should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of other treatment alternatives. In order to minimize the potential growth effects of corticosteroids, children should be titrated to the lowest effective dose [see Warnings and Precautions (5.9)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience with prednisone has not identified differences in responses between the elderly and younger patients. However, the incidence of corticosteroid-induced side effects may be increased in geriatric patients and are dose-related.
Osteoporosis is the most frequently encountered complication, which occurs at a higher incidence rate in corticosteroid-treated geriatric patients as compared to younger populations and in age-matched controls. Losses of bone mineral density appear to be greatest early on in the course of treatment and may recover over time after steroid withdrawal or use of lower doses (i.e., ≤ 5 mg/day).
Prednisone doses of 7.5 mg/day or higher have been associated with an increased relative risk of both vertebral and nonvertebral fractures, even in the presence of higher bone density compared to patients with involution osteoporosis. Routine screening of geriatric patients, including regular assessments of bone mineral density and institution of fracture prevention strategies, along with regular review of prednisone indication should be undertaken to minimize complications and keep the prednisolone dose at the lowest acceptable level.
Co-administration of certain bisphosphonates have been shown to retard the rate of bone loss in corticosteroid-treated males and postmenopausal females, and these agents are recommended in the prevention and treatment of corticosteroid-induced osteoporosis [see Warnings and Precautions (5.6)]. It has been reported that equivalent weight-based doses yield higher total and unbound prednisolone plasma concentrations and reduced renal and non-renal clearance in elderly patients compared to younger populations.
Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Administration
2.3 Method of Administration Prednisone delayed-release tablets are for oral administration. Prednisone delayed-release tablets should be taken daily with food. [see Clinical Pharmacology (12.3) ] Prednisone delayed-release tablets should not be broken, divided, or chewed because the delayed release of prednisone is dependent on an intact coating [see Description (11)] .
US FDA labelDosage forms
Philippines
- Tablet: 1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 50 mg
- Film-coated tablet: 10 mg, 20 mg, 30 mg
- Suspension: 10 mg/5 mL
- Oral solution: 10 mg/5 mL
Registered products in the Philippines
84 products registered with the Food and Drug Administration (FDA) Philippines list Prednisone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products84
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AdresonePrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Foramen Products Corporation | DRP-1063-03 | Sep 19, 2031 | |
AdresonePrednisone | 30 mg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Foramen Products Corporation | DRP-1743-03 | Aug 30, 2029 | |
AlphapredPrednisone | 10 mg / 5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Alpha Farmaceutico Corp.Trader: Westfield Pharmaceuticals, Inc. | DRP-10047-03 | Aug 7, 2028 | |
Alphapred 20Prednisone | 20 mg Film-Coated TabletAlu / PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Alpha Farmaceutico Corp.Trader: Westfield Pharmaceuticals, Inc. | DRP-8440-04 | Feb 8, 2028 | |
AlsonePrednisone | 10 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Pharmahealth EnterprisesTrader: Euro-Health Care Exponents, Inc. | DRP-2811-04 | Jul 31, 2031 | |
BerapredPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Beracah Pharma Phils., IncTrader: Foramen Products Corporation | DRP-1063-04 | Aug 27, 2031 | |
BerapredPrednisone | 30 mg TabletAlu/Clear PVDC Blister Pack x 10's (Box 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Beracah Pharma Phils., Inc.Trader: Foramen Products Corporation | DRP-1743-01 | Aug 30, 2029 | |
BetpredPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Better Option Pharmaceuticals, Inc.Trader: Foramen Products Corporation | DRP-1063-07 | Aug 26, 2031 | |
BiopredPrednisone | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY31050 | Sep 5, 2030 | |
BiopredPrednisone | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-3494 | Mar 30, 2030 | |
BiosonePrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's); Amber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 30 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Nutramedica Inc.Trader: Foramen Products Corporation | DRP-1063 | May 11, 2030 | |
BiosonePrednisone | 30 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Nutramedica Inc.Trader: Foramen Products Corporation | DRP-1743 | Aug 30, 2029 | |
BiosterPrednisone | 5 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY10894-B | Jan 30, 2029 | |
Corpred 10Prednisone | 10 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Westfield Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2811-06 | Jul 30, 2031 | |
CorsonePrednisone | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | All-Bio Pharma, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-3494-06 | Mar 30, 2030 | |
CortPrednisone | 10 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | RL Pharma Enterprises, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2811-03 | Jul 20, 2031 | |
CortPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | RL Pharma Enterprises Inc.Trader: Foramen Products Corporation | DRP-1063-05 | Sep 22, 2031 | |
CortPrednisone | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | RL Pharma Enterprises, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-3494-03 | Mar 30, 2030 | |
CortPrednisone | 30 mg TabletAlu/Clear PVDC Blister Pack X 10's (Box of 100's) | Rx | LLOYD LABORATORIES, INC.Philippines | RL PHARMA ENTERPRISES INC.Trader: FORAMEN PRODUCTS CORPORATION | DRP-1743-02 | Aug 30, 2029 | |
Cortizon 5Prednisone | 5 mg TabletAlu/PVDC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DR-XY42731 | Oct 2, 2028 | |
Cortizon 5Prednisone | 5 mg TabletAlu/PVDC Blister Pack x 20's (Box of 100’s) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma, Inc. | DRP-17684 | Oct 2, 2028 | |
DanasonePrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Dhan-Czar MarketingTrader: Foramen Products Corporation | DRP-1063-08 | Sep 19, 2031 | |
DerpsonPrednisone | 5 mg TabletAlu/PVC Blister Pack x 20’s (Box of 100’s) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-7971 | Aug 27, 2029 | |
DrazonePrednisone | 5 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-5767 | Apr 27, 2027 | |
KodasonePrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Kodapharm Med Corp.Trader: Westfield Pharmaceuticals, Inc. | DRP-10047-01 | Aug 7, 2028 | |
LefesonePrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Meedpharma Medical Supplies & Equipment DistributorTrader: Foramen Products Corporation | DRP-1063-06 | Aug 26, 2031 | |
NonePrednisone | 10 mg TabletAlu/Red Pvc Blister Pack x 20's (Box of 100's) | Rx | Vonwelt, Inc.Philippines | — | DR-XY42512 | Sep 2, 2030 | |
NonePrednisone | 10 mg TabletAlu/Red PVC Blister Pack x 20's (Box of 100's) | Rx | Vonwelt Inc.Philippines | — | DRP-13536 | Sep 2, 2030 | |
NonePrednisone | 10 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2811-02 | Jul 6, 2031 | |
NonePrednisone | 20 mg TabletAluminum Foil Strip x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY37710 | Mar 29, 2030 | |
NonePrednisone | 5 mg TabletAlu-PVC Blister pack x 20's and 25's (Box of 100's) | Rx | Drugmakers Laboratories Inc.Philippines | — | DR-XY42231 | Feb 7, 2037 | |
NonePrednisone | 5 mg TabletAlu/PVC Blister pack x 20's (Box of 100's) | Rx | Drugmakers Laboratories IncPhilippines | TGP Pharma Inc. | DRP-5779-01 | Feb 25, 2030 | |
NonePrednisone | 5 mg TabletFoil Strip x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DRP-931 | Mar 22, 2030 | |
OrapredPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL Box of 1's | Rx | Lloyd Laboratories, Inc.Philippines | Basic Pharmaceutical CorporationTrader: Foramen Products Corporation | DRP-1063-11 | Sep 22, 2031 | |
OrapredPrednisone | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Basic Pharmaceutical CorporationTrader: Euro-Health Care Exponents, Inc. | DRP-3494-05 | Mar 30, 2030 | |
OrapredPrednisone | 5 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Basic Pharmaceutical Corporation | DR-XY18751 | Aug 15, 2029 | |
PRED 1Prednisone | 1 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY29552 | Apr 27, 2029 | |
Pred 10Prednisone | 10 mg TabletClear PVC Film Blister Pack x 20's (Box of 100's and 500's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY23612-B | Apr 22, 2028 | |
Pred 10Prednisone | 10 mg/5 mL SuspensionAmber Bottle x 30 mL & 60 mL | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY26758 | Dec 11, 2030 | |
Pred 20Prednisone | 20 mg Film-Coated TabletBlister Pack x 10's (Box of 100's and 500's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY30359 | Nov 24, 2029 | |
Pred 30Prednisone | 30 mg Film-Coated TabletBlister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY27808 | Sep 4, 2027 | |
Pred 5Prednisone | 5 mg TabletClear PVC/Aluminum Foil Blister Strip x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY27721 | Feb 25, 2031 | |
Pred 50Prednisone | 50 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Prosel Pharmaceuticals & Distributors, Inc. | DR-XY29139 | Nov 10, 2028 | |
PredexPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL Box of 1's | Rx | Lloyd Laboratories, Inc.Philippines | Eadriex Pharmaceuticals Phils., Inc.Trader: Foramen Products Corporation | DRP-1063-09 | Sep 19, 2031 | |
PredfirstPrednisone | 20 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Firstmed Theraconcept Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-8440-02 | Feb 8, 2028 | |
PredixonePrednisone | 10mg TabletAlu/PVC Blister pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | Phil Pharmawealth Inc. | DRP-8907-01 | Jul 6, 2031 | |
PredixonePrednisone | 5 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, IncPhilippines | Phil Pharmawealth, Inc. | DRP-5779-02 | Feb 25, 2030 | |
PredlifePrednisone | 20 mg Film-Coated TabletAlu/PVDC Blister Pacl x 10's (Box of 100's) | Rx | Lloyd Laboratories Inc.Bulacan | Life and Health Source Pharmaceutical Distribution Co.Trader: Westfield Pharmaceuticals, Inc. | DRP-8440-05 | Feb 8, 2028 | |
Predmed 10Prednisone | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Flourish PharmaIndia | Speed Med Pharmaceuticals, Inc.,Importer: Biophil Medical Equipment and Supplies Trading | DRP-16094 | Oct 29, 2029 | |
Predmed 20Prednisone | 20 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Flourish PharmaIndia | Speed Med Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-16093 | Oct 29, 2029 | |
PrednilifePrednisone | 10 mg Film-Coated TabletAlu/Clear PVC Blister pack x 10's (Box of 100's); Alu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Nucare Labs LLPIndia | Biophil Medical Equipment and Supplies Trading | DRP-18669 | Aug 13, 2031 | |
PrednilifePrednisone | 20 mg Film-Coated TabletAlu/Clear PVC Blister pack x 10's (Box of 100's) Alu/Clear PVC Blister pack x 20's (Box of 100's) | Rx | Nucare Labs LLPIndia | Biophil Medical Equipment and Supplies Trading | DRP-18668 | Aug 13, 2031 | |
PrednimedPrednisone | 10 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2811-01 | Jul 15, 2031 | |
PrednimedPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL Box of 1's | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Foramen Products Corporation | DRP-1063-10 | Sep 19, 2031 | |
PrednimedPrednisone | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-3494-01 | Mar 30, 2030 | |
PrednisaphPrednisone | 5 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-8299 | Jan 6, 2031 | |
PrednovaPrednisone | 10mg / 5mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Vitalife Pharma & Medical Supply Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-10047-04 | Aug 7, 2028 | |
Predoque-10Prednisone | 10 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Huazhong Pharmaceutical Co., Ltd.China | Amb Hk Enterprises Inc. | DRP-16558 | Apr 28, 2030 | |
Predoque-30Prednisone | 30 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Huazhong Pharmaceutical Co., Ltd.China | Amb Hk Enterprises Inc. | DRP-16559 | Apr 28, 2030 | |
Predoque-5Prednisone | 5 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Huazhong Pharmaceutical Co., Ltd.China | Amb Hk Enterprises Inc. | DRP-16561 | Apr 28, 2030 | |
Predoque-50Prednisone | 50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Huazhong Pharmaceutical Co., Ltd.China | Amb Hk Enterprises Inc. | DRP-16560 | Apr 28, 2030 | |
PredsterPrednisone | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Medilyn DrugTrader: Euro-Health Care Exponents, Inc. | DRP-3494-02 | Mar 30, 2030 | |
PrendPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-10047 | Aug 7, 2028 | |
PrendPrednisone | 20 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-8440 | Feb 8, 2028 | |
PrendPrednisone | 5 mg TabletBlister Pack x 20's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-2634 | Jul 4, 2027 | |
Prenisaph-10Prednisone | 10 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Ollen Pharma Trading, Inc. | DRP-13468 | Jan 6, 2031 | |
Prenisaph-20Prednisone | 20 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 20's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Ollen Pharma Trading, Inc. | DRP-13467 | Jan 6, 2031 | |
PresonePrednisone | 10 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-8907 | Jun 18, 2030 | |
PresonePrednisone | 10 mg/5 mL Oral Solution (Orange Flavor)Boston Round Amber Glass Bottle with White Aluminum Pilfer-Proof Cap x 60 mL (Box of 1's) | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DRP-10993 | Dec 29, 2028 | |
ProlixPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1’s) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY28837 | Jul 28, 2028 | |
ProlixPrednisone | 20 mg TabletFoil Strip x 10’s (Box of 100’s) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY28527 | Apr 10, 2028 | |
RegisonPrednisone | 20 mg Film-Coated TabletAlu / PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-8440-03 | Feb 8, 2028 | |
Sone-10Prednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's); Amber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 30 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Pharmahealth EnterprisesTrader: Foramen Products Corporation | DRP-1063-12 | Sep 19, 2031 | |
SteerometzPrednisone | 5 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Metz Pharmaceuticals, Inc. | DR-XY16895-B | Oct 15, 2027 | |
Stero-cort 20Prednisone | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | 999 Seth Pharmaceutical Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-3494-07 | Mar 30, 2030 | |
Stero-Cort SPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | 999-Seth Pharmaceutical Inc.Trader: Foramen Products Corporation | DRP-1063-13 | Sep 19, 2031 | |
Sterocort-10Prednisone | 10 mg TabletBlister Pack x 20's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | 999 Seth Pharmaceutical Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-2811 | Sep 5, 2030 | |
SystocorPrednisone | 5 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DRP-5779 | Feb 25, 2030 | |
UnbrandedPREDNISONE | 20 mg TabletAlu/Red Pvc Blister Pack X 20's (Box of 100's) | Rx | Vonwelt Inc.Philippines | — | DRP-13568 | Sep 2, 2030 | |
UnbrandedPrednisone | 20mg TabletAlu/Red Pvc Blister Pack X 20's (Box of 100's) | Rx | Vonwelt Inc.Philippines | — | DR-XY42520 | Sep 2, 2030 | |
UnicortPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle with Lloyd Logo Printed on Aluminum Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Tgp Pharma Inc.Trader: Foramen Products Corporation | DRP-1063-01 | Sep 19, 2031 | |
ViscortPrednisone | 10 mg/5 mL SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Vispomed CorporationTrader: Westfield Pharmaceuticals, Inc. | DRP-10047-02 | Aug 7, 2028 | |
Zetricort 20Prednisone | 20 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100's); Alu/Clear PVC Blister Pack x 20’s (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Roymed PharmaceuticalImporter: Ollen Pharma Trading, Inc. | DRP-13467-02 | Jan 6, 2031 | |
Zetricort 5Prednisone | 5 mg TabletAlu/Clear PVC blister pack x 20’s (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Roymed PharmaceuticalImporter: Nelpa Lifesciences, Inc. | DRP-8299-02 | Jan 6, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Delayed-release Tablets Prednisone delayed release tablets, 1 mg: White to off-white colored, round, unscored, delayed release tablet, debossed with "1" on one side and plain on other side, mottled appearance, free from physical defects. Prednisone delayed release tablets, 2 mg: Light peach to peach colored, round, unscored, delayed release tablet, debossed with "2" on one side and plain on other side, mottled appearance, free from physical defects. Delayed-release tablets: 1 mg, and 2 mg prednisone (3)
Warnings/Precautions
- Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia: Monitor patients for these conditions with chronic use. Taper doses gradually for withdrawal after chronic use. (5.1)
- Immunosuppression and Increased Risk of Infection: Increased susceptibility to new infection and increased risk of exacerbation, dissemination, or reactivation of latent infection. Signs and symptoms of infection may be masked. (5.2)
- Elevated blood pressure, salt and water retention, and hypokalemia: Monitor blood pressure and sodium, potassium serum levels (5.3)
- GI perforation: increased risk in patients with certain GI disorders. Signs and symptoms may be masked. (5.4)
- Behavioral and mood disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis. Existing conditions may be aggravated. (5.5)
- Decreases in bone density: Monitor bone density in patients receiving long term corticosteroid therapy. (5.6)
- Ophthalmic effects: May include cataracts, infections, and glaucoma. Monitor intraocular pressure if corticosteroid therapy is continued for more than 6 weeks (5.7)
- Live or live attenuated vaccines: Do not administer to patients receiving immunosuppressive doses of corticosteroids. (5.8)
- Negative effects on growth and development: Monitor pediatric patients on long-term corticosteroid therapy. (5.9)
- …
5.1 Alterations in Endocrine Function
5.1 Alterations in Endocrine Function Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia. Monitor patients for these conditions with chronic use. Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment.
Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. If the patient is receiving corticosteroids already, dosage may have to be increased.
Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Mineralocorticoid supplementation is of particular importance in infancy. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.
5.2 Immunosuppression and Increased Risk of Infection
5.2 Immunosuppression and Increased Risk of Infection Corticosteroids, including prednisone delayed-release tablets, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Increase the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal.
The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider prednisone delayed-release tablets withdrawal or dosage reduction as needed. Tuberculosis If prednisone delayed-release tablets are used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.
Closely monitor such patients for reactivation. During prolonged prednisone delayed-release tablets therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including prednisone delayed-release tablets.
In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: If a prednisone delayed-release tablets-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
If a prednisone delayed-release tablets-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including prednisone delayed-release tablets.
Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with prednisone delayed-release tablets. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.
Fungal Infections Corticosteroids, including prednisone delayed-release tablets, may exacerbate systemic fungal infections; therefore, avoid prednisone delayed-release tablets use in the presence of such infections unless prednisone delayed-release tablets are needed to control drug reactions. For patients on chronic prednisone delayed-release tablets therapy who develop systemic fungal infections, prednisone delayed-release tablets withdrawal or dosage reduction is recommended.
Amebiasis Corticosteroids, including prednisone delayed-release tablets, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating prednisone delayed-release tablets in patients who have spent time in the tropics or patients with unexplained diarrhea.
Strongyloides Infestation Corticosteroids, including prednisone delayed-release tablets, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
Cerebral Malaria Avoid corticosteroids, including prednisone delayed-release tablets, in patients with cerebral malaria.
5.3 Alterations in Cardiovascular/Renal Function
5.3 Alterations in Cardiovascular/Renal Function Corticosteroids can cause elevation of blood pressure, salt, and water retention, and increased excretion of potassium and calcium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary.
These agents should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.
5.4 Use in Patients with Gastrointestinal Disorders
5.4 Use in Patients with Gastrointestinal Disorders There is an increased risk of gastrointestinal perforation in patients with certain GI disorders. Signs of GI perforation, such as peritoneal irritation may be masked in patients receiving corticosteroids. Corticosteroids should be used with caution if there is a probability of impending perforation, abscess, or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; and active or latent peptic ulcer.
5.5 Behavioral and Mood Disturbances
5.5 Behavioral and Mood Disturbances Corticosteroids use may be associated with central nervous system effects ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
5.6 Decrease in Bone Density
5.6 Decrease in Bone Density Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in children and adolescents and the development of osteoporosis at any age.
Special consideration should be given to patients at increased risk of osteoporosis (i.e., postmenopausal women) before initiating corticosteroid therapy and bone density should be monitored in patients on long term corticosteroid therapy.
5.7 Ophthalmic Effects
5.7 Ophthalmic Effects Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes.
Intraocular pressure may become elevated in some individuals. If corticosteroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation. Corticosteroids should not be used in active ocular herpes simplex.
5.8 Vaccination
5.8 Vaccination Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered; however, the response to such vaccines cannot be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.
While on corticosteroid therapy, patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.
5.9 Effect on Growth and Development
5.9 Effect on Growth and Development Long-term use of corticosteroids can have negative effects on growth and development in children. Growth and development of pediatric patients on prolonged corticosteroid therapy should be carefully monitored.
5.10 Embryo-Fetal Toxicity
5.10 Embryo-Fetal Toxicity Prednisone can cause fetal harm when administered to a pregnant woman. Human studies suggest a small but inconsistent increased risk of orofacial clefts with use of corticosteroids during the first trimester of pregnancy. Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring.
Intrauterine growth restriction and decreased birth weight have also been reported with corticosteroid use during pregnancy, however, the underlying maternal condition may also contribute to these risks. If this drug is used during pregnancy, or if the patient becomes pregnant while using this drug, advise the patient about the potential harm to the fetus [see Use in Specific Populations (8.1)].
5.11 Neuromuscular Effects
5.11 Neuromuscular Effects Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.
An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis.
Elevation of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.
5.12 Kaposi's Sarcoma
5.12 Kaposi's Sarcoma Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.
Drug interactions
- Anticoagulant agents: May enhance or diminish anticoagulant effects. (7.4)
- Antidiabetic agents: May increase blood glucose concentrations. Dose adjustments of antidiabetic agents may be required. (7.5)
- CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (7.7, 7.8)
- Cyclosporine: Increase in activity of both, cyclosporine and corticosteroid when administered concurrently. Convulsions have been reported with concurrent use. (7.10)
- NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (7.13)
7.1 Aminoglutethimide
7.1 Aminoglutethimide Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression.
7.2 Amphotericin B Injection
7.2 Amphotericin B Injection There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure [see Drug Interactions (7.14)].
7.3 Anticholinesterase Agents
7.3 Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
7.4 Anticoagulant Agents
7.4 Anticoagulant Agents Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.
7.5 Antidiabetic Agents
7.5 Antidiabetic Agents Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
7.6 Antitubercular Drugs
7.6 Antitubercular Drugs Serum concentrations of isoniazid may be decreased.
7.7 CYP 3
7.7 CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
7.8 CYP 3
7.8 CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects.
7.9 Cholestyramine
7.9 Cholestyramine Cholestyramine may increase the clearance of corticosteroids.
7.10 Cyclosporine
7.10 Cyclosporine Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use.
7.11 Digitalis
7.11 Digitalis Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.
7.12 Estrogens, Including Oral Contraceptives
7.12 Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
7.13 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Including Aspirin and Salicylates
7.13 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Including Aspirin and Salicylates Concomitant use of aspirin or other nonsteroidal anti-inflammatory drugs and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
The clearance of salicylates may be increased with concurrent use of corticosteroids; this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
7.14 Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B)
7.14 Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia.
7.15 Skin Tests
7.15 Skin Tests Corticosteroids may suppress reactions to skin tests.
7.16 Toxoids and Live or Attenuated Vaccines
7.16 Toxoids and Live or Attenuated Vaccines Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible [see Warnings and Precautions (5.8)].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
( 7.5 ) CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment.
Adverse reactions
Common adverse reactions for corticosteroids include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain. Allergic Reactions: Anaphylaxis, angioedema Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scalp, edema, facial erythema, hyper or hypopigmentation, impaired wound healing, increased sweating, petechiae and ecchymoses, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria Endocrine: Abnormal fat deposits, decreased carbohydrate tolerance, development of Cushingoid state, hirsutism, manifestations of latent diabetes mellitus and increased requirements for insulin or oral hypoglycemic agents in diabetics, menstrual irregularities, moon facies, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery or illness), suppression of growth in children Fluid and Electrolyte Disturbances: Fluid …
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of prednisone delayed-release tablets was evaluated in 375 rheumatoid arthritis patients in two controlled trials.
Patients treated with prednisone delayed-release tablets ranged in age from 20 to 80 years (median age 56 years), with 85% female, 99% Caucasian, 1% African-American, and < 1% Asian. Patients received prednisone delayed-release tablets 3 mg to 10 mg once daily at 10 pm; the majority (84%) received ≤ 5 mg. The clinical trial experience did not raise new safety concerns beyond those already established for immediate-release prednisone.
6.2 Postmarketing Experience
6.2 Postmarketing Experience Adverse reactions have been identified during post approval use of prednisone delayed-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The postmarketing experience has not raised new safety concerns beyond those already established for immediate-release prednisone.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings from human and animal studies, corticosteroids, including prednisone delayed-release tablets, can cause fetal harm when administered to a pregnant woman (see Data) [see Warnings and Precautions (5.10)]. Published epidemiological studies suggest a small but inconsistent increased risk of orofacial clefts with use of corticosteroids during the first trimester.
Intrauterine growth restriction and decreased birth weight have also been reported with maternal use of corticosteroids during pregnancy; however, the underlying maternal condition may also contribute to these risks (see Clinical Considerations). Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring (see Data).
Advise a pregnant woman about the potential harm to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinical recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Fetal/Neonatal Adverse Reactions Infants born to pregnant women who have received corticosteroids should be carefully monitored for signs and symptoms of hypoadrenalism [see Warnings and Precautions (5.1)] Data Human Data Published epidemiological studies on the association between prednisolone and fetal outcomes have reported inconsistent findings and have important methodological limitations. Multiple cohort and case-controlled studies in humans suggest that maternal corticosteroid use during the first trimester increases the incidence of cleft lip with or without cleft palate from about 1/1000 infants to 3-5/1000 infants; however, a risk for orofacial clefts has not been observed in all studies.
Methodological limitations of these studies include non-randomized design, retrospective data collection, and the inability to control for confounders such as underlying maternal disease and use of concomitant medications. Two prospective case control studies showed decreased birth weight in infants exposed to maternal corticosteroids in utero.
In humans, the risk of decreased birth weight appears to be dose related and may be minimized by administering lower corticosteroid doses. It is likely that underlying maternal conditions contribute to intrauterine growth restriction and decreased birth weight, but it is unclear to what extent these maternal conditions contribute to the increased risk of orofacial clefts.
Animal Data Prednisolone, the active metabolite of prednisone, administered during the period of organogenesis, has been shown to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. In teratogenicity studies, cleft palate along with elevation of fetal lethality (or increase in resorptions) and reductions in fetal body weight were seen in rats at maternal doses of 30 mg/kg (equivalent to 290 mg in a 60 kg individual based on mg/m 2 body surface comparison) and higher.
Cleft palate was observed in mice at a maternal dose of 20 mg/kg (equivalent to 100 mg in a 60 kg individual based on mg/m 2 comparison). Additionally, constriction of the ductus arteriosus has been observed in fetuses of pregnant rats exposed to prednisolone. Prednisone delayed-release tablets was not formally evaluated in animal reproduction studies.
Mechanism of action
12.1 Mechanism of Action Naturally occurring corticosteroids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, such as prednisone, are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.
Corticosteroids, such as prednisone, cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli. Prednisone is a synthetic adrenocortical steroid drug with predominantly corticosteroid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones' normal functions; they are seen only after administration of large therapeutic doses of the drug.
The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Depressed production of eosinophils and lymphocytes occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated.
Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids.
Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.
US FDA labelPharmacokinetics
Prednisone delayed-release tablets at dose levels of 1 mg, 2 mg, and 5 mg showed dose-proportionality in terms of peak and systemic exposure (C max , AUC 0-∞ , and AUC 0-last ) for the parent drug prednisone as well as for the active metabolite prednisolone. figure1 Metabolism Prednisone is completely converted to the active metabolite prednisolone, which is further metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates.
Excretion The terminal half-life of both prednisone and prednisolone from the administration of prednisone delayed-release tablets was 2-3 hours, which is comparable to that from the IR formulation.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The pharmacokinetic profile of prednisone delayed-release tablets has an approximately 4-hour lag time from that of immediate-release prednisone formulations. While the pharmacokinetic profile of prednisone delayed-release tablets when given with food differs in terms of lag time from IR prednisone, its absorption, distribution, and elimination processes are comparable.
Absorption Prednisone is released from prednisone delayed-release tablets when taken with food approximately 4 hours after oral ingestion. This causes a delay in the time until peak plasma concentrations (T max) are achieved. Median T max of prednisone delayed-release tablets in 27 healthy male subjects was 6.0 - 6.5 hours compared to 2.0 hours for an immediate-release (IR) formulation.
Subsequently, prednisone was absorbed at the same rate as the IR formulation. Peak plasma concentrations (C max) and exposure, as indicated by AUC 0-last and AUC 0-∞, were comparable for both prednisone IR and prednisone delayed-release tablets administered 2.5 hours after a light meal or with normal meal (Figure 1). Figure 1.
Mean Plasma Levels of Prednisone After a Single Dose of 5 mg Prednisone Administered as a 5 mg Prednisone Delayed-Release Tablet or a 5 mg Immediate-Release (IR) Tablet A: 5 mg IR tablet under fasting conditions, administered at 2 am, B: 5 mg prednisone delayed-release tablets, administered 2.5 hours after a light evening meal, and C: 5 mg prednisone delayed-release tablets administered immediately after dinner In a study with 24 healthy subjects, oral absorption of prednisone from prednisone delayed-release tablets was significantly affected by the intake of food. Under standard fasting conditions, both the maximum plasma concentration (C max) and the bioavailability of prednisone delayed-release tablets were significantly lower than under fed conditions, shortly after intake of a high fat meal.
Prednisone delayed-release tablets at dose levels of 1 mg, 2 mg, and 5 mg showed dose-proportionality in terms of peak and systemic exposure (C max, AUC 0-∞, and AUC 0-last) for the parent drug prednisone as well as for the active metabolite prednisolone. figure1 Metabolism Prednisone is completely converted to the active metabolite prednisolone, which is further metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates. The exposure of prednisolone is 4-6 fold higher than that of prednisone.
Excretion The terminal half-life of both prednisone and prednisolone from the administration of prednisone delayed-release tablets was 2-3 hours, which is comparable to that from the IR formulation. Special Populations The effects of gender, age, renal impairment, and hepatic impairment on the pharmacokinetics of prednisone or prednisolone after administration of prednisone delayed-release tablets have not been evaluated.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Prednisone 5 mg Tablet | ₱0.53–₱1.90Reference ₱0.59 | per tablet | DPRI procurement range |
| Prednisone 10 mg Tablet | ₱0.80–₱4.40Reference ₱2.45 | per tablet | DPRI procurement range |
| Prednisone 10 mg/5 mL, 60 mL Suspension | ₱75.00–₱140.00Reference ₱102.10 | per unit | DPRI procurement range |
| Prednisone 20 mg Tablet | ₱2.36–₱7.00Reference ₱2.36 | per tablet | DPRI procurement range |
| 5 mg tablet | ₱1.75 | per tablet | PhilHealth GAMOT fixed fee |
| 10 mg tablet | ₱3.25 | per tablet | PhilHealth GAMOT fixed fee |
| 10 mg/5 mL suspension in 60 mL | ₱134.25 | per unit | PhilHealth GAMOT fixed fee |
| 20 mg tablet | ₱6.50 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Prednisone |
| PNF listing | Oral: 5 mg, 10 mg and 20 mg tablet |
| PNF listing | Oral: 10 mg/5 mL suspension, 60 mL |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Prednisone delayed release · Dr. Reddys Laboratories Inc. [US FDA-approved label, version 5, September 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01bdc479-1f1f-af94-837c-12e7e861321a
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .



